Notice2022-08150
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 18, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 74 (Monday, April 18, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 74 (Monday, April 18, 2022)]
[Notices]
[Pages 22933-22934]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-08150]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Yogikala Prabhu, Ph.D., 301-761-7789;
<a href="/cdn-cgi/l/email-protection#c9b9bba8aba1bcb0a689a7a0a8a0ade7a7a0a1e7aea6bf"><span class="__cf_email__" data-cfemail="6a1a180b08021f13052a04030b030e44040302440d051c">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases (NIAID),
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Novel Methods of MHC-I--LILRB Checkpoint Inhibition
Description of Technology: The technology encompasses antibodies
and methods that may overcome the shortcomings of commercial checkpoint
inhibitors (CPIs). Scientists at NIAID have identified MHC-I specific
antibodies that selectively inhibit interactions with inhibitory
leukocyte immunoglobin-like receptors (LILRs) but not T-cell receptors.
Administration of the antibodies increased proliferation and activation
of both innate and adaptive immune system cells, and lead to anti-tumor
and anti-viral activity in an array of relevant mouse models of
disease.
Immune CPIs that target PD-1/PD-L1, CTLA-4 and other well-known
molecules can provide significant clinical benefit as part of a mono or
combination immunotherapy regimen. However, many patients do not
respond to treatment, leading to an ongoing search for novel checkpoint
targets. One attractive family of targets are the inhibitory Leukocyte
Immunoglobin-like receptors (LILRB1-5). LILRB1, LILRB2, and LILRB5 can
inhibit immune cell function by binding to many MHC-I subtypes.
However, LILRB1/2/5 expression is variable and the three members cannot
be targeted by any single blocking anti-LILB antibody, possibly
limiting the efficacy of targeting LILRBs. NIAID scientists have
circumvented these issues by identifying antibodies that can inhibit
LILRB function by binding to MHC-I without interfering with T-cell
receptor engagement.
To date, the MHC-I specific antibodies have been shown to induce
activation and proliferation of human T cells and NK cells in
xenogeneic models using NSG mice.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37
[[Page 22934]]
CFR part 404, as well as for further development and evaluation under a
research collaboration.
Potential Commercial Applications:
<bullet> Anti-tumor checkpoint inhibitor
<bullet> Anti-viral checkpoint inhibitor
Competitive Advantages:
<bullet> Activation of innate (NK) and adaptive (CD8\+\ and CD4\+\)
immune cell types
<bullet> Causes proliferation and activation of immune effector cells
regardless of target expression in tumors
Development Stage:
<bullet> Pre-clinical
Inventors: Ethan M. Shevach, M.D. (NIAID), Abir Panda, Ph.D.
(NIAID), David H. Margulies, M.D., Ph.D. (NIAID), and Kannan Natarajan,
Ph.D. (NIAID).
Publications: Panda, Abir, et al. ``Cutting Edge: Inhibition of the
interaction of NK inhibitory receptors with MHC class I augments anti-
viral and anti-tumor immunity.'' J Immunol. 2020.04.01.437942
Intellectual Property: HHS Reference No. E-160-2021-0; US
provisional application No. 63/262,120 filed on October 5, 2021.
Licensing Contact: To license this technology, please contact
Yogikala Prabhu, Ph.D., 301-761-7789; <a href="/cdn-cgi/l/email-protection#05757764676d707c6a456b6c646c612b6b6c6d2b626a73"><span class="__cf_email__" data-cfemail="14646675767c616d7b547a7d757d703a7a7d7c3a737b62">[email protected]</span></a>, and
reference E-160-2021-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Yogikala Prabhu, Ph.D., 301-761-7789;
<a href="/cdn-cgi/l/email-protection#f0808291929885899fb09e99919994de9e9998de979f86"><span class="__cf_email__" data-cfemail="37474556555f424e5877595e565e5319595e5f19505841">[email protected]</span></a>.
Dated: April 12, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-08150 Filed 4-15-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 18, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.